Bortezomib

Bortezomib in the glossary for Waldenström's macroglobulinemia

Bortezomib is a proteosome inhibitor.

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells.¹ Inhibition of the proteasome results in cell cycle arrest and apoptosis. Bortezomib is administered as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone. Bortezomib is indicated for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib was approved for medical use in the European Union in 2004.²

Glossary overview

References

1.Bortezomib SmPC. Available from; https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf. Accessed November 12th, 2021.

2.EMEA Scientific Discussion – Bortezomib. Available from; https://www.ema.europa.eu/en/documents/scientific-discussion-variation/velcade-h-c-539-ii-0005-epar-scientific-discussion-variation_en.pdf. Accessed November 12th, 2021.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.